<DOC>
	<DOCNO>NCT00165646</DOCNO>
	<brief_summary>To investigate efficacy safety 4-week treatment 5 mg/day 10 mg/day E3810 ( Pariet ( Rabeprazole Sodium ) ) patient non-erosive gastroesophageal reflux disease multicenter , randomize , double-blind , comparative study .</brief_summary>
	<brief_title>A Comparative Study Efficacy Safety E3810 Patients With Non-erosive Gastroesophageal Reflux Disease</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>The patient include outpatient meet follow criterion . No specific gender ask . &lt; For observation period &gt; 1 . Patients `` heartburn '' 2 day week consecutive week 3 week prior preobservation screening . If day screen day start observation ( date registration ) different , heartburn must continuously present inbetween period . 2 . Patients meet 1 ) 2 ) ; 1 ) The symptom burn sensation arise stomach low chest . 2 ) The symptom tends appear frequently aggravate eating , bend body forward , and/or press abdomen . ( 3 ) Patients categorize `` grade M '' ( discolor type : minimal change ) accord Los Angeles System ( 2nd Modification ) Classification Reflux Esophagitis . ( 4 ) Patients 20 year old old time obtain consent . ( 5 ) Patients informed objective detail study give write consent study entry . &lt; For treatment period &gt; 1 . Patients `` heartburn '' 2 day week 7 day immediately treatment period ( observation period ) . 2 . Patients `` heartburn diary '' completely fill 7 day treatment period ( observation period ) . If observation period 8 day longer , heartburn diary entry fulfil 80 % observation period . 3 . Patients 80 % good drug compliance antacid observation period . Patients meet follow criterion exclude study . 1 . Patients keep adequate entry heartburn diary . 2 . Patients strongly complain `` feeling heavy stomach '' and/or `` abdominal bloating . '' 3 . Patients complication history psychiatric psychosomatic disease ( e.g. , manicdepressive psychosis , obsessivecompulsive neurosis , others ) antidepressant antianxiety agent ( accepted hypnotic treatment ) . 4 . Patients undergone Helicobacter pylorus eradication therapy , less 6 month elapse end H. pylori eradication therapy begin observation period . : The day 6 month earlier , day end 6 month earlier end month . 5 . Patients open gastric duodenal ulcer . 6 . Patients acute gastritis . 7 . Patients history surgical intervention affect peptic secretion ( e.g. , upper gastrointestinal tract resection and/or vagotomy ) . 8 . Patients Barrett 's esophagus , esophageal stenosis , pyloric stenosis . 9 . Patients scleroderma . 10 . Patients history complication angina pectoris . 11 . Patients work night ( work nightshift ) . 12 . Patients receive proton pump inhibitor ( PPIs ) within 3 week prior preobservation screen 13 . Patients need NSAIDs ( except topical preparation ) , steroid ( except topical preparation ) , and/or aspirin treatment every day 14 . Patients receive dialysis therapy 15 . Patients serious complication cardiovascular disease ( e.g. , myocardial infarction ) , hematological disorder ( e.g. , aplastic anemia ) , renal disease ( e.g. , acute chronic renal failure ) , hepatic disease ( e.g. , cirrhosis ) , malignant tumor . 16 . Patients know hypersensitivity antacid PPIs . 17 . Patients pregnant childbearing potential , wish become pregnant lactating study period . 18 . Patients receive another investigational drug receive another investigational drug within 6 month prior preobservation screening : Registration allow day 6 month earlier , day end 6 month earlier end month . 19 . Patients judge ineligible study entry investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>non-erosive gastroesophageal reflux disease</keyword>
	<keyword>NERD</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>rabeprazole</keyword>
</DOC>